Delving into the Latest Updates on Beijing Bio-Targeting Therapeutics Technology with Synapse

Overview

Tags

Nervous System Diseases

Digestive System Disorders

Neoplasms

Oncolytic virus

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Oncolytic virus	1

Top 5 Target	Count

IL-12R(Interleukin-12 receptor)	1

Ⅰb期剂量递增主要研究目的：评价BioTTT001治疗复发/进展性高级别脑胶质瘤患者的安全性、耐受性，确定剂量限制性毒性（DLT）和最大耐受剂量（MTD）和/或II期推荐剂量（RP2D）。Ⅱ期剂量扩展主要研究目的：评价BioTTT001治疗复发/进展性高级别脑胶质瘤患者的有效性。

[Translation]

The main purpose of the Phase Ib dose escalation study is to evaluate the safety and tolerability of BioTTT001 in the treatment of patients with recurrent/progressive high-grade brain glioma, and to determine the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) and/or the Phase II recommended dose (RP2D). The main purpose of the Phase II dose expansion study is to evaluate the effectiveness of BioTTT001 in the treatment of patients with recurrent/progressive high-grade brain glioma.

Start Date26 Nov 2024

Sponsor / Collaborator

Beijing Bio-Targeting Therapeutics Technology

NCT06763965

/ Enrolling by invitationPhase 1/2

A Phase Ib/Ⅱ Clinical Study to Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of Recombinant Human NsIL12 Oncolytic Adenovirus Injection (BioTTT001) in Patients with Recurrent/progressive High-grade Glioma.

This study is a single-arm, open-label, dose-escalation and dose-expanding Phase Ⅰb/Ⅱ clinical study to evaluate the safety, tolerability, biodistribution characteristics and preliminary efficacy of recombinant human nsIL12 oncolytic adenovirus injection (BioTTT001) in patients with recurrent/progressive high-grade glioma.

Start Date26 Nov 2024

Sponsor / Collaborator

Beijing Bio-Targeting Therapeutics Technology

NCT06215846

/ Enrolling by invitationPhase 1

Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetics of Recombinant Human NsIL12 Oncolytic Adenovirus Injection (BioTTT001) in Patients with Malignant Solid Tumors

This is a Phase 1 open-label study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) at dose of 5×10∧9VP、5×10∧10VP、5×10∧11VP in Patients With Malignant Solid Tumors. Subjects will be treated with a single dose of BioTTT001 Injection after the screening period.

Start Date07 May 2024

Sponsor / Collaborator

Beijing Bio-Targeting Therapeutics Technology

100 Clinical Results associated with Beijing Bio-Targeting Therapeutics Technology

Login to view more data

0 Patents (Medical) associated with Beijing Bio-Targeting Therapeutics Technology

Login to view more data

100 Deals associated with Beijing Bio-Targeting Therapeutics Technology

Login to view more data

100 Translational Medicine associated with Beijing Bio-Targeting Therapeutics Technology

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data